CORCEPT THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
CORT$73.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Common Stock · Additional Paid-in Capital · Treasury Stock · Accumulated Other Comprehensive (Loss) Income · Retained Earnings · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balance at December 31, 2024 | 105,113 | $136 | $832,108 | $(696,173) | $(217) | $543,735 | $679,589 |
| Issuance of common stock under incentive award plan | 1,712 | 1 | 12,899 | — | — | — | 12,900 |
| Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock | (341) | — | — | (21,086) | — | — | (21,086) |
| Repurchase of common stock in connection with Stock Repurchase Program | (500) | — | — | (27,433) | — | — | (27,433) |
| Stock-based compensation | — | — | 15,687 | — | — | — | 15,687 |
| Vesting of RSAs in connection with ESPP | — | — | 2,172 | — | — | — | 2,172 |
| Other comprehensive gain, net of tax | — | — | — | — | 909 | — | 909 |
| Net income | — | — | — | — | — | 20,547 | 20,547 |
| Balance at March 31, 2025 | 105,984 | $137 | $862,866 | $(744,692) | $692 | $564,282 | $683,285 |
| Common Stock · Additional Paid-in Capital · Treasury Stock · Accumulated Other Comprehensive Income (Loss) · Retained Earnings · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balance at December 31, 2023 | 103,405 | $133 | $738,515 | $(635,078) | $609 | $402,526 | $506,705 |
| Issuance of common stock under incentive award plan | 786 | — | 3,485 | — | — | — | 3,485 |
| Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock | (143) | — | 2,032 | (5,586) | — | — | (3,554) |
| Repurchase of common stock in connection with Stock Repurchase Program | (20) | — | — | (476) | — | — | (476) |
| Excise tax related to net share repurchases | — | — | — | 81 | — | — | 81 |
| Stock-based compensation | — | — | 12,929 | — | — | — | 12,929 |
| Vesting of RSAs in connection with ESPP | — | — | 1,283 | — | — | — | 1,283 |
| Other comprehensive loss, net of tax | — | — | — | — | (351) | — | (351) |
| Net income | — | — | — | — | — | 27,762 | 27,762 |
| Balance at March 31, 2024 | 104,028 | $133 | $758,244 | $(641,059) | $258 | $430,288 | $547,864 |
The accompanying notes are an integral part of these condensed consolidated financial statements
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.